Dr. Deepa Jagadeesh discusses Ordspono's potential FDA approval for relapsed/refractory follicular lymphoma, highlighting its manageable toxicity and low CRS rate.
24mon MSN
President Donald Trump’s volatile tariff threats are unleashing historic jumps in public anxiety, with the potential to ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback